Brawn Biotech Ltd

BSE: 530207

19

total announcements

BRAWN.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 19 Nov 2026

Market Cap

₹6 Cr

P/E (TTM)

7.3

EPS (TTM)

₹2.89

52W Low

₹17.71

52W High

₹26.64

Dividend Yield

0.00%

Beta

0.11

Price / Book

1.2

Return on Equity

19.86%

Revenue (TTM)

₹18 Cr

Gross Margin

14.11%

Operating Margin

-1.63%

BSECompany UpdateRegulatory5 Nov 2026

Brawn Biotech Ltd

Intimation regarding non-applicability of regulation 23(9)

Brawn Biotech Ltd has submitted an undertaking to the BSE, stating that the company is not required to file related party transactions as per Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, due to its paid-up share capital and net worth not exceeding Rs. 10 crore and Rs. 25 crore, respectively, as on March 31, 2026.

Read more →📎 1 attachment
BSEResultResults5 Nov 2026

Brawn Biotech Ltd

Outcome of Board Meeting

Brawn Biotech Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs. 61,274.78 lakhs and profit from ordinary activities before tax at Rs. 18.46 lakhs.

Read more →📎 1 attachment
BSEBoard MeetingResults5 Nov 2026

Brawn Biotech Ltd

Outcome Of Board Meeting Held On 5th November, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For Quarter Ended September 30, 2026.

Brawn Biotech Ltd has announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company reported a profit from ordinary activities before tax of ₹18.46 lakhs and a profit for the period of ₹18.46 lakhs. The results were reviewed by the audit committee and approved by the board of directors on November 5, 2026.

Read more →📎 1 attachment
BSEBoard MeetingResults29 Oct 2026

Brawn Biotech Ltd

Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results Of The Company For The Quarter Ended September 30, 2026

Brawn Biotech Ltd has informed BSE that its Board of Directors will meet on November 5, 2026, to consider and approve the un-audited financial results for the quarter ended September 30, 2026. The trading window will remain closed from October 29 to November 16, 2026.

Read more →📎 1 attachment
BSECompany Update15 Oct 2026

Brawn Biotech Ltd

Intimation under Reg 74(5)

Brawn Biotech Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as required by the BSE.

Read more →📎 1 attachment
BSEAGM/EGMResults29 Sept 2026

Brawn Biotech Ltd

Scrutinizers Report attached along with voting results for 41st AGM

Brawn Biotech Ltd has announced the voting results and scrutinizer's report for its 41st Annual General Meeting (AGM) held on September 29, 2026, through video conferencing. All items of business were approved by the members, and the details of voting results are enclosed in the prescribed format.

Read more →📎 1 attachment
BSEAGM/EGM29 Sept 2026

Brawn Biotech Ltd

Proceedings of 41st AGM

Brawn Biotech Ltd held its 41st Annual General Meeting (AGM) on September 29, 2026, through video conferencing. The meeting was attended by 44 members, and the resolutions related to audited financial statements, director appointment, statutory auditor appointment, and managerial remuneration were passed.

Read more →📎 1 attachment
BSEAGM/EGM29 Sept 2026

Brawn Biotech Ltd

Outcome of 41st Annual General Meeting

Brawn Biotech Ltd held its 41st Annual General Meeting on September 29, 2026, through VC/OAVM, and all resolutions were passed with a requisite majority.

Read more →📎 1 attachment
BSEInsider Trading / SASTResults28 Sept 2026

Brawn Biotech Ltd

Closure of Trading Window for quarter ended 30.09.2026

Brawn Biotech Ltd has announced the closure of its trading window for insiders from October 1, 2026, until 48 hours after the declaration of un-audited financial results for the quarter and half year ended September 30, 2026.

Read more →📎 1 attachment
BSECompany Update2 Sept 2026

Brawn Biotech Ltd

Letters sent to shareholders as per Reg 36

Brawn Biotech Ltd has issued letters to shareholders who have not registered their email address, providing a weblink for accessing the Notice of the 41st Annual General Meeting and Annual Report for the financial year 2025-26.

Read more →📎 1 attachment
BSECompany Update2 Sept 2026

Brawn Biotech Ltd

Newspaper Publication for 41st Notice of AGM.

Brawn Biotech Ltd has published a newspaper advertisement for its 41st Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The company has also been involved in a copyright dispute related to an AI-generated artwork, with the Copyright Office rejecting the application for registration of the artwork as the AI system, DABUS, is not recognized as the legal author under Indian copyright law.

Read more →📎 1 attachment
BSEOthersResults1 Sept 2026

Brawn Biotech Ltd

ANNUAL REPORT FOR FY 2025-26

Brawn Biotech Ltd has released its annual report for FY 2025-26, along with the notice of its 41st Annual General Meeting. The meeting will be held on September 29, 2026, through video conferencing. The report includes the audited financial statements, directors' report, and other relevant information.

Read more →📎 1 attachment
BSEAGM/EGMResults1 Sept 2026

Brawn Biotech Ltd

Notice of 41st AGM to be held on 29.09.2026

Brawn Biotech Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on 29th September 2026. The meeting will consider the audited financial statements for the financial year ended 31st March 2026, appointment of a director, and managerial remuneration of Mr. Amit Kumar.

Read more →📎 1 attachment
BSEResultResults13 Aug 2026

Brawn Biotech Ltd

Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.

Brawn Biotech Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors in a meeting held on August 13, 2026. The company reported revenue from operations of ₹ 217.18 crore, a decrease of 0.53% from the previous quarter. The net profit for the quarter stood at ₹ 4.05 crore, a decrease of 56.25% from the previous quarter.

Read more →📎 1 attachment
BSEBoard MeetingResults13 Aug 2026

Brawn Biotech Ltd

Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.

Brawn Biotech Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹ 217.18 crore and profit before tax at ₹ 4.15 crore. The company's board of directors has approved the financial results and also considered and approved the Boards' Report for the financial year ended March 31, 2026.

Read more →📎 1 attachment